News Search Results
Apr 16, 2025, 07:25 ET Global Health Innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact
future of health. Winners of the ADGHW Innovation Awards 2025 were recognised for pioneering solutions in digital health, biotechnology, and diagnostics, receiving global recognition and a share of the $200,000 prize fund.
More news about: Abu Dhabi Global Health Week (ADGHW)
Apr 16, 2025, 07:01 ET Grown Alchemist Launches in US on Nordstrom.com
Grown Alchemist, the beauty brand that engineers plant-powered solutions using cutting edge biotechnology to achieve total skin health, has expanded its footprint in the US, launching with luxury retailer, Nordstrom, on their e-commerce platform.
More news about: Grown Alchemist
Apr 16, 2025, 06:59 ET Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the
More news about: Q32 Bio
Apr 16, 2025, 04:00 ET Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development
commercial supply. Meeting Global Supply Needs Polpharma Biologics, a major player in the global biosimilar market and the largest biotechnology company in Poland, brings a robust pipeline that includes multiple early-stage and late-stage biosimilars, along
More news about: Chime Biologics
Apr 15, 2025, 16:05 ET Flamingo Therapeutics Announces Poster Presentation on the Immune-Modulatory Effects of Danvatirsen at the American Association for Cancer Research (AACR) Annual Meeting
undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Abrdn (formerly funds managed by Tekla Capital Management LLC), Andera Partners, Bpifrance Large Venture, Bpifrance through
More news about: Flamingo Therapeutics
Apr 15, 2025, 14:44 ET Celebrated Intellectual Property Attorney Malaika Tyson Joins Lathrop GPM's Chicago Office
patent litigation and European Patent Office patent opposition practice. She represents clients in various areas – particularly in the life science, biotechnology, pharmaceutical, chemical and material sciences and consumer goods industries. "I am excited to join the excellent IP attorneys at Lathrop
More news about: Lathrop GPM
Apr 15, 2025, 09:55 ET ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and reminds investors of the May 20, 2025 deadline to seek the
More news about: Faruqi & Faruqi, LLP
Apr 15, 2025, 09:04 ET Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative disease
SEATTLE, April 15, 2025 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company targeting RNA with small molecules, announced today a collaboration with Daiichi Sankyo focused on a key neurodegeneration target.
More news about: Wayfinder Biosciences, Inc.
Apr 15, 2025, 09:00 ET Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria
Calif., April 15, 2025 /PRNewswire/ -- Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient
More news about: Evommune, Inc
Apr 15, 2025, 08:35 ET Pilatus Biosciences to Present Research on PLT012 at AACR 2025
metabolic and immunological diseases. About Pilatus Biosciences Pilatus Biosciences, a U.S./Swiss-based preclinical stage biotechnology company founded in 2022 with origins at the Ludwig Institute for Cancer Research (Lausanne). The company develops first-in-class biologics targeting
More news about: Pilatus Biosciences
Apr 15, 2025, 08:33 ET Shaunna Balady and Kelly Kunkle Join sbLiftOff as Senior SMEs
commercial B2B services. A trusted advisor, sbLiftOff has closed transactions in a wide variety of industries, including IT, data analytics, logistics, biotechnology, facilities maintenance, cyber security and human capital solutions. Contact: sbLiftOff Public Relations April
More news about: sbLiftOff
Apr 15, 2025, 08:01 ET Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon Biologics Ltd.
Apr 15, 2025, 07:01 ET MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability
April 15, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose (MAD) Part 2
More news about: MetaVia Inc.
Apr 15, 2025, 07:00 ET ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Ventures
Kingdom, April 15, 2025 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI)
More news about: ThirtyFiveBio
Apr 15, 2025, 07:00 ET Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
Mass., April 15, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will host a virtual key opinion leader (KOL) event featuring
More news about: Leap Therapeutics, Inc.
Apr 15, 2025, 04:00 ET myTomorrows and Scout Clinical Partner to Provide Cross-Border Patient Recruitment for Clinical Trials
education. Since 1995, we've been a trusted partner in customer service, regulatory compliance, and project delivery for leading pharmaceutical and biotechnology companies. Our deep understanding of international regulations and adaptable network of resources is built on operational experience in 109 countries.
More news about: myTomorrows and Scout Clinical
Apr 14, 2025, 21:00 ET JelloX Biotech Establishes US Research Base
Taiwan-based startup at the forefront of cancer pathology, is announcing it will open a lab in the Discovery Oasis biotechnology space in Phoenix, Arizona.
More news about: JelloX Biotech Inc.
Apr 14, 2025, 20:51 ET U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's biosimilar to Humira® (adalimumab)
ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Apr 14, 2025, 13:53 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States
More news about: Pomerantz LLP
Apr 14, 2025, 10:07 ET ProBio to Present Data on Its CD3 Agonistic Single Domain Antibody Platform for Accelerated Development of T Cell Engager Multi-Specific Antibodies
development risks and accelerating timelines. One notable customer of ProBio’s antibody discovery platform is ABL Bio, a leading biotechnology company developing bispecific antibody therapeutics for immune-oncology and neurodegenerative diseases. Jonghwa Won, Ph.D., EVP and Chief
More news about: ProBio Inc.
Apr 14, 2025, 10:01 ET Glove Box Market to Reach $3.1 billion, Globally, by 2034 at 5.1% CAGR: Allied Market Research
projected to manifest the highest CAGR of 5.8% from 2025 to 2034. Pharmaceutical and biotechnology segment dominated the market in 2024 By end user, the pharmaceutical and biotechnology segment held the highest market share in 2024 accounting for the largest share in 2024, contributing
More news about: Allied Market Research
Apr 14, 2025, 09:51 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
Apr 14, 2025, 09:30 ET Skunk Works® and Arquimea Develop AI Capable ISR Platforms
Arquimea ARQUIMEA is a global technology company driven by innovation. We develop cutting-edge Artificial Intelligence, Quantum, Robotics and Biotechnology solutions and products for high-demand industries such as Aerospace and Defense & Security. Our research and development capabilities are supported
More news about: Lockheed Martin Aeronautics
Apr 14, 2025, 08:30 ET Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia
April 14, 2025 /PRNewswire/ -- Cellenkos® Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory (Treg) cell therapies for inflammatory disease areas of high unmet needs and
More news about: Cellenkos, Inc.
Apr 14, 2025, 08:30 ET Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio
India. Intas' biosimilars are manufactured at Intas Pharmaceuticals' European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit
More news about: Accord BioPharma